Compare IQV & AMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IQV | AMP |
|---|---|---|
| Founded | 1982 | 1894 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.6B | 41.3B |
| IPO Year | 2013 | 2009 |
| Metric | IQV | AMP |
|---|---|---|
| Price | $203.92 | $489.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | $227.13 | ★ $544.91 |
| AVG Volume (30 Days) | ★ 1.5M | 617.2K |
| Earning Date | 05-05-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 1.43% |
| EPS Growth | 4.67 | ★ 9.77 |
| EPS | 1.61 | ★ 9.68 |
| Revenue | $9,739,000,000.00 | ★ $18,911,000,000.00 |
| Revenue This Year | $6.77 | $1.79 |
| Revenue Next Year | $5.89 | $4.20 |
| P/E Ratio | $129.54 | ★ $52.46 |
| Revenue Growth | ★ 41.60 | 5.49 |
| 52 Week Low | $154.50 | $422.37 |
| 52 Week High | $247.05 | $550.18 |
| Indicator | IQV | AMP |
|---|---|---|
| Relative Strength Index (RSI) | 66.57 | 61.06 |
| Support Level | $159.91 | $487.47 |
| Resistance Level | $209.48 | $509.70 |
| Average True Range (ATR) | 7.02 | 13.04 |
| MACD | 2.45 | 4.63 |
| Stochastic Oscillator | 84.77 | 68.59 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.